Inflammation and pharmacokinetics: potential implications for HIV-infection.
The physiological changes accompanying inflammation may alter the pharmacokinetics (PK) of certain medications. Individuals infected with HIV have chronically elevated inflammatory markers despite viral suppression following effective antiretroviral therapy (ART), as well as age-related inflammation. Understanding the potential clinical implications of inflammation on the PK of medications is important for understanding dose-response relationships and necessitates future research. Areas covered: An extensive literature search was carried out using PubMed and associated bibliographies to summarize the current state of knowledge regarding altered PK in response to inflammation and its application to the field of HIV. Expert opinion: Preclinical and clinical studies show that inflammation leads to a downregulation of certain drug metabolizing enzymes and both up and down regulation of transporters depending on the transporter and cell type. Decreased gastric acidity, fluid shifts, and plasma protein alterations also occur with inflammation, leading to potential absorption, distribution, and clearance changes. More research is needed including controlled PK studies to address the clinical relevance of these observations, especially in the aging HIV-infected population. Results from future studies will enable us to better predict drug concentrations in individuals with inflammation, in line with efforts to provide personalized pharmacotherapy in our healthcare system.
a Skaggs School of Pharmacy and Pharmaceutical Sciences Department of Pharmaceutical Sciences , University of Colorado , Anschutz Medical Campus, USA.
Sharon M
SM
Seifert
b School of Medicine, Division of Infectious Diseases , University of Colorado , Anschutz Medical Campus, USA.
Jose R
JR
Castillo-Mancilla
b School of Medicine, Division of Infectious Diseases , University of Colorado , Anschutz Medical Campus, USA.
Kristine M
KM
Erlandson
a Skaggs School of Pharmacy and Pharmaceutical Sciences Department of Pharmaceutical Sciences , University of Colorado , Anschutz Medical Campus, USA.
Peter L
PL
Anderson
D000367:Age Factors; D019380:Anti-HIV Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D001692:Biological Transport; D004305:Dose-Response Relationship, Drug; D015536:Down-Regulation; D004798:Enzymes / Q000378:metabolism; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007249:Inflammation / Q000150:complications* / Q000473:pathology
D019380:Anti-HIV Agents; D004798:Enzymes
HIV; antiretrovirals; inflammation; pharmacokinetics